

**Table 1. Baseline Characteristics According to Prior Treatment Response**

Variable	Previous Response					Total
	Null Response T12PR24 n = 24	Null Response T12PR48 n = 27	Partial Response n = 29	Viral Breakthrough n = 8	Relapse n = 29	
Age, mean (years) (range)	49 (19–60)	51 (34–63)	51 (27–62)	50 (46–55)	50 (31–60)	50 (19–63)
BMI, mean kg/m <sup>2</sup> (range)	30 (21–57)	30 (21–41)	28 (20–37)	25 (18–28)	26 (19–39)	28 (18–57)
Sex male, n (%)	14 (58)	23 (85)	22 (76)	4 (50)	18 (62)	81 (69)
Race, n (%)						
White	22 (92)	24 (89)	27 (93)	7 (88)	26 (90)	106 (91)
Black	2 (8)	3 (11)	1 (3)	1 (12)	2 (7)	9 (8)
Other	0 (0)	0 (0)	1 (3)	0 (0)	1 (3)	2 (2)
Ethnicity, n (%)						
Hispanic/Latino	2 (8)	2 (7)	3 (10)	0 (0)	2 (7)	9 (8)
Not Hispanic/Latino	22 (92)	25 (93)	26 (90)	8 (100)	27 (93)	108 (92)
Geographic region, n (%)						
Europe	1 (4)	7 (26)	6 (21)	0 (0)	11 (38)	25 (21)
North America	23 (96)	20 (74)	23 (79)	8 (100)	18 (62)	92 (79)
HCV genotype 1 subtype, n (%)						
1a	14 (58)	16 (59)	17 (59)	5 (62)	17 (59)	69 (59)
1b	8 (33)	10 (37)	7 (24)	3 (38)	10 (34)	38 (32)
1, unknown	2 (8)	1 (4)	5 (17)		2 (7)	10 (9)
HCV RNA ≥800,000 IU/mL	23 (96)	27 (100)	25 (86)	3 (38)	19 (66)	97 (83)
Stage of fibrosis, n (%)						
None or minimal fibrosis	5 (21)	6 (22)	8 (28)	2 (25)	8 (28)	29 (25)
Portal fibrosis	8 (33)	10 (37)	9 (31)	2 (25)	15 (52)	44 (38)
Bridging fibrosis	9 (38)	9 (33)	7 (24)	4 (50)	5 (17)	34 (29)
Cirrhosis	2 (8)	2 (7)	5 (17)	0 (0)	1 (3)	10 (9)